Kapil Dhingra founded and is the head of KAPital Consulting, a healthcare consulting firm. Dr. Dhingra also serves on several life science company boards, including Advanced Accelerator Applications, Exosome Diagnostics Inc., Autolus, and Five Prime, Inc. He previously served on the Boards of several successful companies, including Biovex, Micromet, Algeta, and, YM Biosciences, that were acquired by major pharmaceutical companies. Prior to joining AAA, Dr. Dhingra worked for over 25 years in oncology clinical research and drug development. His experience includes nine years at Hoffman-La Roche, where he served in various positions, including Vice President, Head of the Oncology Disease Biology Leadership Team and Head of Oncology Clinical Development. Prior to that, he worked as a Senior Clinical Research Physician at Eli Lilly and Company. Before joining industry, Dr. Dhingra was on the faculty of The University of Texas MD Anderson Cancer Center for 8 years where he pursued translational and clinical research career in addition to patient care responsibilities. Dr. Dhingra specialized in internal medicine and medical oncology. He holds an MD (MBBS) degree from the All India Institute of Medical Sciences in New Delhi, India, with subsequent residency in internal medicine at Lincoln Medical and Mental Health Center in New York City, New York and New York Medical College in Valhalla, New York, and was a Fellow in hematology/oncology at Emory University School of Medicine in Atlanta, Georgia.